DR DANIELA STANEVA HOPE FOR PARKINSON'S

“Hope for Parkinson’s” explores the most promising frontiers in Parkinson’s disease treatment — highlighting a global shift from symptom management to true disease modification and neurorestoration. This presentation reviews key advances across clinical, molecular, and technological domains, including: Global prevalence and burden of Parkinson’s disease Neuroprotective potential of GLP-1 receptor agonists such as lixisenatide The AAV2-AADC gene therapy trial for restoring dopamine synthesis Ambroxol as a modulator of lysosomal function and GBA1-related pathology LRRK2 kinase inhibitors targeting genetic forms of Parkinson’s disease Anti-α-synuclein immunotherapies designed to prevent pathological protein spread Focused ultrasound ablation as a non-invasive neurosurgical intervention Adapted (closed-loop) deep brain stimulation (DBS) for personalized modulation The FDA-approved foslevodopa/foscarbidopa subcutaneous pump for continuous delivery Stem cell–based regeneration and neural repair strategies The Stanford glove project and other wearable neurorehabilitation tools Presented as part of the AMIQT Neurology Rotation, this talk integrates recent breakthroughs in neuroscience, pharmacology, and neuroengineering — emphasizing the growing synergy between research innovation and clinical application. You can contact me at: dany.staneva@gmail.com